A Phase 4 interventional study of Group Therapy Program and semaglutide in Bipolar I Disorder, Bipolar II Disorder and Schizo Affective Disorder, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-11.
Sponsored by Mayo Clinic · Phase 4, Interventional, and Treatment
How we know · 12 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Bipolar Disorder by Mayo Clinic — 5 open to participants now, 6 under way, none of them phase 3. Bipolar Disorder · Mayo Clinic.
Among the 13 studies in Bipolar Disorder by Mayo Clinic, this one is the 2nd largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2026, is one of 5 in phase 4, and was the 11th registered.
1,687 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.
Browse Bipolar Disorder studies →5 of the 13 studies in Bipolar Disorder by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18–65
Mayo Clinic · Sites in United States
Ages 18–50
Mayo Clinic · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 207 Bipolar Disorder studies recruiting now, 60 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 64 across 1,282 interventional studies indexed under Bipolar Disorder.
Median enrollment 35 across the 12 interventional studies, 200 across the 1 observational. Of the 6 that completed or were terminated, 4 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
Mayo Clinic is the lead sponsor of 3,272 studies on the registry; 672 are open to participants now.
Of its 452 completed or terminated interventional studies of FDA-regulated products, 322 (71%) have results posted.
1 of the studies in Bipolar Disorder by Mayo Clinic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03573349Mayo ClinicKetamine Associated ACC GABA and Glutamate Change and Depression Remission: | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Bipolar Disorder by Mayo Clinic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to identify the specific characteristics (phenotypes) that may be useful to help select the right medication for weight loss, and to study the effect of individualized guided medication in patients with bipolar disorder ages 18-65. The main questions it aims to answer are:
Participation will last for about 20 weeks and includes 8 in-person study visits, up to 11 phone call visits, and 13 virtual group therapy sessions. The first visit lasts about 2 hours and includes going over the informed consent form, a diagnostic interview to confirm diagnosis, gathering vital signs, mood questionnaires, an ECG, a blood draw, and urine drug and pregnancy tests (if applicable). The second visit lasts about 6-7 hours and involves multiple procedures and completing questionnaires to determine which study drug would allow participants to lose weight most effectively. At the third visit, participants will be assigned to take one of three FDA approved medications for weight loss: Semaglutide (Wegovy®), Naltrexone/Bupropion (Contrave®), or Phentermine/Topiramate (Qsymia®). It is possible that participants could be assigned to a group that receives no study medication. All participants will be enrolled in a 12-week virtual group therapy program targeted for weight loss. On this third visit the investigators will also gather vital signs, and participants will give a sample of blood. After the third visit, participants will come in for study visits every 4 weeks for 20 weeks (5 visits) to assess medication adherence, vitals, and answer questions about mood and eating (participants will also give a sample of blood at the 8-week and 20-week visits). For participants assigned to a study medication, the study team will call every week for the first 2 months (excluding in-person visit weeks) to assess mood and safety. After the first 2 months, the study team will call the participant every two weeks in between in-person visits. Participants will be compensated for time spent in this study. Participants assigned to a study medication will also be given the option to participate in the open-label phase of the study, which involves 3 follow-up visits (weeks 24, 36, and 48) over 7 months after the 20-week trial. During this phase, participants can continue to take the medication through their clinical care provider.
This is a single-site, open-label, non-randomized interventional pilot study evaluating a phenotype-guided pharmacological approach to obesity in adults with bipolar disorder (BD). The study aims to assess the distribution of obesity phenotypes and the efficacy, safety, and tolerability of individualized anti-obesity pharmacotherapy in this population. A total of 100 participants with BD and comorbid obesity will be enrolled and stratified into one of four obesity phenotypes: Hungry Brain (abnormal satiation), Hungry Gut (abnormal postprandial satiety), Emotional Hunger (emotional eating), and Slow Burn (low resting energy expenditure).
Participants will undergo comprehensive obesity phenotyping, including indirect calorimetry, gastric emptying scintigraphy, DEXA scans, ad libitum buffet meal testing, and validated behavioral questionnaires. Based on phenotype classification, participants will receive one of the following FDA-approved anti-obesity medications (AOMs): phentermine-topiramate ER (Qsymia®), semaglutide (Wegovy®), or naltrexone-bupropion ER (Contrave®). Participants with the Slow Burn phenotype will receive behavioral and lifestyle interventions only.
All participants will engage in a 12-week virtual behavioral intervention program led by a multidisciplinary team, including a psychologist and a registered dietitian. The program includes weekly group sessions focused on nutrition, physical activity, cognitive restructuring, and relapse prevention.
A comprehensive data safety monitoring plan (DSMP) is in place, including bi-monthly reviews by a multidisciplinary team. Adverse events (AEs) and serious adverse events (SAEs) will be monitored and reported per institutional and federal guidelines. Participants will be withdrawn from the study if they experience treatment-emergent mania, severe depression, suicidality, or other safety concerns.
The statistical analysis plan includes descriptive statistics, repeated measures models, and subgroup analyses by phenotype and BD subtype. Missing data will be handled using multiple imputation or maximum likelihood methods. No formal multiplicity adjustments will be applied due to the exploratory nature of the study.
This study addresses a critical gap in obesity treatment for individuals with serious mental illness by integrating precision medicine with psychiatric care. The findings will inform future randomized controlled trials and contribute to the development of personalized obesity interventions in psychiatric populations.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
By meeting the satiety/return to hunger (Hungry Gut) phenotype, participants will take Semaglutide (Wegovy) and attend a 12-week group therapy session for the 16-week clinical trial.
Behavioral: Group Therapy Program · Drug: semaglutide
By meeting the behavioral/psychological (Emotional Hunger) phenotype, participants will take Naltrexone/Bupropion (Contrave) and attend a 12-week group therapy session for the 16-week clinical trial.
Behavioral: Group Therapy Program · Drug: naltrexone and bupropion (combination)
By meeting the satiation (Hungry Brain) phenotype, participants will take Phentermine/Topiramate (Qsymia) and attend a 12-week group therapy session for the 16-week clinical trial.
Behavioral: Group Therapy Program · Drug: Phentermine-Topiramate
By meeting the slow burn phenotype, participants will attend a 12-week group therapy session for the 16-week clinical trial.
Behavioral: Group Therapy Program
a 12-week group therapy program centered around weight loss and healthy eating.
Brand name: Wegovy
Drug pages: PhentermineStudies of PhenterminePhentermine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · TopiramateStudies of TopiramateTopiramate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Brand name: Qsymia
Drug pages: NaltrexoneStudies of NaltrexoneNaltrexone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · BupropionStudies of BupropionBupropion pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Brand name: Contrave
Describe the distribution of obesity phenotypes (hungry brain, hungry gut, emotional hunger and slow burn) in patients with BD and obesity, with the goal of identifying predominant phenotype patterns within this clinical population.
Time frame: From enrollment through the end of the 20-week intervention.
Compare the distribution of obesity phenotypes (hungry brain, hungry gut, emotional hunger, and slow burn) in patients with BD and obesity and non-BD participants published in previously cohorts.
Time frame: From the start of intervention (week 0) through the end of intervention (week 20).
The feasibility and tolerability of anti-obesity medication (AOM) in patients with BD, assessed by adherence rates and reports on adverse events.
Time frame: from the start of intervention (week 0) through the end of intervention (week 20).
Total body weight loss (in kilograms) from baseline to end point in patients with BD and obesity.
Time frame: From the start of intervention (week 0) through the end of intervention (week 20).
The proportion of treatment responders, defined as individuals achieving >4% total body weight loss, from baseline to end point in patients with BD and obesity.
Time frame: From the start of intervention (week 0) through the end of intervention (week 20).
Changes in metabolic parameters from baseline to end point in patients with BD.
Time frame: From the start of intervention (week 0) through the end of intervention (week 20).
Changes in eating behavior from baseline to endpoint in patients with BD using validated questionnaires.
Time frame: From the start of intervention (week 0) through the end of intervention (week 20).
Changes in mood symptoms from baseline to endpoint in patients with BD using validated questionnaires.
Time frame: From the start of intervention (week 0) through the end of intervention (week 20).
Changes in mitochondrial biomarkers from baseline to end point in patients with BD and obesity.
Time frame: From the start of intervention (week 0) through the end of intervention (week 20)
Changes in stress related biomarkers from baseline to end point in patients with BD and obesity.
Time frame: From the start of intervention (week 0) through the end of intervention (week 20)
Surrogate biomarkers of obesity phenotypes.
Time frame: From the start of intervention (week 0) through the end of intervention (week 20).
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Feb 2028, 24 months after the start.
Of 39 non-industry phase 4 interventional studies under Bipolar Disorder, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 61. This study's planned 24 months is below that.
Counting every sponsor, half of 44 studies reached it within 43 months; a quarter within 25 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Semaglutide · Phentermine · Topiramate · Naltrexone · Bupropion